{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:58:41Z","timestamp":1791356321383,"version":"4.3.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.humpath.2017.06.018","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T14:32:24Z","timestamp":1499869944000},"page":"14-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Pathologic findings in breast, fallopian tube, and ovary specimens in non- BRCA hereditary breast and\/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C , BARD1 , BRIP1 , PALB2 , MUTYH , or CHEK2"],"prefix":"10.1016","volume":"70","author":[{"given":"J. Kenneth","family":"Schoolmeester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Moyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKinsey L.","family":"Goodenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Keeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie N.","family":"Bakkum-Gamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2017.06.018_bb0005","series-title":"SEER cancer statistics review","author":"Howlader","year":"1975"},{"key":"10.1016\/j.humpath.2017.06.018_bb0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2013.50.9257","article-title":"American Society of Clinical Oncology expert statement: collection and use of a cancer family history for oncology providers","volume":"32","author":"Lu","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ogc.2012.02.006","article-title":"Hereditary gynecologic cancers: risk assessment, counseling, testing and management","volume":"39","author":"Ballinger","year":"2012","journal-title":"Obstet Gynecol Clin N Am"},{"key":"10.1016\/j.humpath.2017.06.018_bb0020","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/j.seminoncol.2016.10.001","article-title":"Updates on breast cancer genetics: clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer","volume":"43","author":"Cobain","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.20892\/j.issn.2095-3941.2016.0002","article-title":"Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing","volume":"13","author":"Stanislaw","year":"2016","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.humpath.2017.06.018_bb0030","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","article-title":"Multigene panel testing detects equal rates of pathogenic BRCA1\/2 mutations and has a higher diagnostic yield compared to limited BRCA1\/2 analysis alone in patients at risk for hereditary breast cancer","volume":"22","author":"Kapoor","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0035","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0040","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0045","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/90.15.1138","article-title":"Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations","volume":"90","author":"Lakhani","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2017.06.018_bb0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/PAS.0000000000000369","article-title":"Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma","volume":"39","author":"Howitt","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00428-014-1619-1","article-title":"Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers","volume":"465","author":"Gevensleben","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2017.06.018_bb0065","doi-asserted-by":"crossref","first-page":"R120","DOI":"10.1186\/bcr3589","article-title":"RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families","volume":"15","author":"Schnurbein","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.humpath.2017.06.018_bb0070","series-title":"WHO classification of tumours of female reproductive organs","author":"Kurman","year":"2014"},{"key":"10.1016\/j.humpath.2017.06.018_bb0075","series-title":"WHO classification of tumours of the breast","author":"Lakhani","year":"2012"},{"key":"10.1016\/j.humpath.2017.06.018_bb0080","unstructured":"Daly MB, Pilarski R, Axilbund JE, et al. NCCN clinical practice guidelines in oncology: genetic\/familial high-risk assessment: breast and ovarian Version 2.2017."},{"key":"10.1016\/j.humpath.2017.06.018_bb0085","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","article-title":"Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond","volume":"1","author":"Hansford","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0100","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/cncr.25876","article-title":"Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer","volume":"117","author":"Xie","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2017.06.018_bb0105","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/90.8.606","article-title":"Multiple primary cancers in families with Li-Fraumeni syndrome","volume":"90","author":"Hisada","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2017.06.018_bb0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1947601911413466","article-title":"Li-Fraumeni syndrome","volume":"2","author":"Malkin","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.humpath.2017.06.018_bb0115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/cge.12548","article-title":"Genetic testing for RAD51C mutations: in the clinic and community","volume":"88","author":"Sopik","year":"2015","journal-title":"Clin Genet"},{"key":"10.1016\/j.humpath.2017.06.018_bb0120","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2007.12.5922","article-title":"CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls","volume":"26","author":"Weischer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0125","first-page":"3606","article-title":"Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers","volume":"9","author":"Palacios","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.06.018_bb0130","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/cncr.26506","article-title":"MutYH mutation carriers have increased breast cancer risk","volume":"118","author":"Rennert","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2017.06.018_bb0135","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/sj.bjc.6605966","article-title":"A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants","volume":"103","author":"Theodoratou","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2017.06.018_bb0140","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.2015.63.3594","article-title":"Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen general population study","volume":"34","author":"Naslund-Koch","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0145","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2006.06.3024","article-title":"Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation","volume":"25","author":"Schmidt","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.06.018_bb0150","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1086\/426403","article-title":"CHEK2 is a multiorgan cancer susceptibility gene","volume":"75","author":"Cybulski","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.humpath.2017.06.018_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-004-3778-2","article-title":"Pathology of breast cancer in women with constitutional CHEK2 mutations","volume":"90","author":"Huzarski","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2017.06.018_bb0160","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ijc.20638","article-title":"Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients","volume":"113","author":"Kilpivaara","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2017.06.018_bb0165","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1038\/sj.onc.1209875","article-title":"Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations","volume":"25","author":"Honrado","year":"2006","journal-title":"Oncogene"},{"issue":"Suppl. 2","key":"10.1016\/j.humpath.2017.06.018_bb0170","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1525-1438.2006.00694.x","article-title":"Association between the CHEK2*1100delC germ line mutation and estrogen receptor status","volume":"16","author":"de Bock","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.humpath.2017.06.018_bb0175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/jmg.2004.019737","article-title":"Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant","volume":"41","author":"de Bock","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.humpath.2017.06.018_bb0180","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1078-0432.CCR-05-2230","article-title":"Characterization of familial non-BRCA1\/2 breast tumors by loss of heterozygosity and immunophenotyping","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.06.018_bb0185","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","volume":"16","author":"LaDuca","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.humpath.2017.06.018_bb0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10689-013-9684-1","article-title":"Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from central and Eastern Europe","volume":"13","author":"Noskowicz","year":"2014","journal-title":"Familial Cancer"},{"key":"10.1016\/j.humpath.2017.06.018_bb0195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/bjc.2013.295","article-title":"Tumour morphology predicts PALB2 germline mutation status","volume":"109","author":"Teo","year":"2013","journal-title":"Br J Cancer"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771730240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771730240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T03:54:18Z","timestamp":1535601258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681771730240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":39,"alternative-id":["S004681771730240X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2017.06.018","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and\/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2017.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}